A Dec. 26 article, Top Five Large-Cap Stocks, incorrectly referred to Noble Corp. (NE) as Noble Energy (NBL). Both are drilling companies. TheStreet.com regrets the error. (Corrected Dec. 28)

A Dec. 24 article,

Kass Katch of the Week: Short OZM, incorrectly listed

Och-Ziff Capital Management Group's

TST Recommends

(OZM) assets under management; they are $33 billion as of Dec. 4. The article also said compensation represents more than 50% of revenue; it should have said that expenses, which includes compensation, represents more than 50% of revenue. Finally, the article said the company has underperformed in all periods; the article should have said it underperformed in the 1-year, 3-year and 5-year periods.

TheStreet.com

regrets the error.

(Corrected Dec. 24)

A Dec. 20 article,

'Fast Money' Recap: Volatility to Rise, offered the wrong timeframe for an earnings-per-share growth estimate.

CSX

(CSX) CEO Michael Ward is looking for EPS growth of 15%-17% (on a compound annual growth rate, or CAGR, basis) through 2010, not 2008 as originally reported.

TheStreet.com

regrets the error.

(Corrected Dec. 21)

A Dec. 20 column,

Top 10 Stocks With Big Insider Buying, Buybacks, misstated the amount of

GE's

(GE) new quarterly dividend. The company raised the payment from 28 cents to 31 cents, not to 28 cents as originally stated.

TheStreet.com

regrets the error.

(Corrected Dec. 20)

A Dec. 18 column,

Top Warren Buffett Short-Squeeze Plays, misidentified

H&R Block

(HRB) as a current Buffett holding. The investor sold his stake in the company earlier this year.

TheStreet.com

regrets the error.

(Corrected Dec. 18)

A Dec. 13 article,

Thursday's Late Winners & Losers, incorrectly stated that

Novell

(NOVL) revised downward its full-year guidance. In fact, it introduced new guidance for fiscal 2008, and the figures used for comparison pertained to 2007.

TheStreet.com

regrets the error.

(Corrected Dec. 14)

A Dec. 10 article,

Monday's Late Winners & Losers, incorrectly stated that

Medarex

(MEDX) and

Bristol-Myers Squibb's

(BMY) ipilimumab compound failed the primary endpoint in all three registrational trials cited. In fact, it failed only one of those trials.

TheStreet.com

regrets the error. (Corrected Dec. 11)

A Dec. 7 article,

Friday's Financial Winners & Losers, incorrectly stated that the pricing of

Fannie Mae's

(FNM) planned share offering represented a discount to the stock's last closing price. Since the offering is for preferred stock, however, the two figures do not correspond.

TheStreet.com

regrets the error.

(Corrected Dec. 7)

A Nov. 27 article,

Six Florida Banks Depositors Should Worry About, incorrectly identified Oculina Bank of Fort Pierce, Fla., as potentially lacking sufficient capital to weather the downturn in the housing market. This was based on an erroneous calculation that Oculina's ratio of nonperforming assets to core capital and reserves was 76%. In fact, as of Sept. 30, the ratio was 27.8%, and the institution should not have been mentioned in the story.

TheStreet.com

regrets the error.

(Corrected Dec. 5)

A Dec. 3 article,

Santarus, Glaxo Ink Zegerid Deal, misidentified a company CEO in a quote taken from a conference call. It was

Santarus'

(SNTS) Gerald Proehl, not

GlaxoSmithKline's

(GSK) Jean-Pierre Garnier.

TheStreet.com

regrets the error.

(Corrected Dec. 3)